샘플 요청 목록

 카트 문의
시장보고서
상품코드
1731987

카테터 관련 혈류감염증 시장

Catheter-Related Bloodstream Infections
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 384 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 카테터 관련 혈류감염증 시장은 2030년까지 19억 달러에 달할 전망

2024년에 15억 달러로 추정되는 세계의 카테터 관련 혈류감염증 시장은 2030년에는 19억 달러에 달하며, 분석 기간인 2024-2030년의 CAGR은 4.0%로 성장할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 항미생물제는 CAGR 4.8%를 기록하며, 분석 기간 종료까지 12억 달러에 달할 것으로 예측됩니다. 항생제 락 요법 분야의 성장률은 분석 기간 중 CAGR 2.7%로 추정됩니다.

미국 시장은 3억 9,890만 달러로 추정, 중국은 CAGR 7.5%로 성장 예측

미국의 카테터 관련 혈류감염증시장은 2024년에 3억 9,890만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 3억 8,000만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 7.5%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.6%와 3.1%로 예측됩니다. 유럽에서는 독일이 CAGR 2.3%로 성장할 것으로 예측됩니다.

세계의 카테터 관련 혈류감염증(CRBSI) 시장 - 주요 동향과 촉진요인 정리

카테터 관련 혈류 감염이 왜 중환자 치료 및 병원 감염 관리에서 지속적인 문제가 되는가?

카테터 관련 혈류감염(CRBSI)은 임상현장, 특히 중환자실, 종양병동, 장기요양시설에서 이환율, 사망률, 의료비 증가의 심각한 원인이 되고 있습니다. 이러한 감염은 혈관내 카테터에 병원균이 정착하여 발생하며, 전신 혈류 감염을 일으켜 치료 결과를 악화시키고 입원 기간을 연장시킵니다. 중심정맥카테터(CVC)는 약물 투여, 비경구영양, 혈행동태 모니터링에 널리 사용되므로 CRBSI는 심각한 병원내 감염 위험으로 병원의 감염관리 프로토콜에 계속 부담을 주고 있습니다.

인식의 향상에도 불구하고 무균 삽입술의 불완전성, 카테터 삽입 시간의 장기화, 항균제 내성 등으로 인해 CRBSI의 세계 부담은 여전히 지속되고 있습니다. 의료 시스템이 품질 지표, 환자 안전, 비용 절감을 우선순위에 두면서 예방 가능한 감염을 최소화해야 할 필요성은 더욱 커지고 있으며, CRBSI를 표적으로 하는 고급 예방 툴, 진단 및 번들 케어 솔루션에 대한 수요는 지속적으로 증가하고 있습니다.

카테터 재료, 항균 코팅, 감염 감시의 혁신이 CRBSI 예방을 어떻게 개선하고 있는가?

의료기기 제조업체들은 미생물의 부착과 생물막 형성을 억제하는 항균 및 방부 코팅(은 설파디아진, 클로르헥시딘, 미노사이클린 리팜핀 등)을 사용하여 카테터 기술을 발전시키고 있습니다. 이러한 코팅이 적용된 카테터는 혈관 접근의 기능을 손상시키지 않으면서 감염률을 낮추기 때문에 위험도가 높은 환경에서 채택되고 있습니다. 카테터 삽입 키트, 고정 기구, 투명 드레싱 재료의 개선으로 감염 장벽 보호가 더욱 강화되고 있습니다.

전자건강기록(EHR)과 연동된 감염 모니터링 시스템 및 실시간 분석 플랫폼도 CRBSI의 조기 발견 및 추적을 지원합니다. 표준화된 중심정맥관 번들, 임상적 판단 지원 툴, 간호사 주도의 제거 프로토콜이 도입되어 정주 치료의 규정 준수와 책임성을 강화합니다. 또한 현장 진단 툴와 신속 배양 시스템은 적시에 병원균을 식별하고 항생제를 적시에 투여하여 환자 결과를 개선하는 데 도움이 됩니다.

CRBSI 예방 및 관리 솔루션 수요는 어디에서 증가하고 있으며, 어떤 임상 환경에서 도입이 진행되고 있는가?

북미는 잘 확립된 병원 품질 보고 프레임워크와 엄격한 CMS 및 CDC 가이드라인에 힘입어 전 세계 CRBSI 예방 노력을 주도하고 있습니다. 미국은 코팅 카테터, 진단 테스트, 감염 모니터링 소프트웨어에 대한 수요를 지속적으로 주도하고 있습니다. 유럽은 카테터 케어 번들 채택이 증가하고 있으며, 지역 전체에서 환자 안전에 대한 노력이 진행되고 있습니다. 아시아태평양은 특히 인도, 중국, 일본 등의 국가에서 감염 관리 시장의 강력한 성장을 목격하고 있으며, ICU 인프라의 확대와 수술 건수 증가로 인해 CRBSI 예방에 대한 우선순위가 높아지고 있습니다.

주요 임상 환경으로는 중환자실, 종양과, 투석센터, 장기 급성기 병원 등이 있으며, 중심정맥 접근이 일반적이고 환자의 취약성이 높은 환경입니다. 또한 재택 수액 요법 및 외래 의료 서비스로 인해 CRBSI 위험 관리의 범위가 병원의 벽을 넘어 확장되고 있으며, 휴대용 감염 예방 솔루션 및 환자 교육 툴에 대한 수요가 증가하고 있습니다.

카테터 관련 혈류감염증 시장의 세계 성장 원동력은?

세계 CRBSI 시장은 혈관 접근 장비 사용 증가, 병원내 감염(HAI)에 대한 인식 증가, 감염 관리 벤치마크를 충족하기 위한 규제 압력에 의해 주도되고 있습니다. 의료 서비스 프로바이더들이 예방 가능한 위험을 줄이고 임상 결과를 최적화하는 데 집중하면서, 피복 카테터, 고정 시스템, 직원 교육 프로토콜을 결합한 번들 솔루션에 대한 투자가 증가하고 있습니다. 치료비 증가, 벌칙, 사회적 비난 등 CRBSI로 인한 경제적 부담은 효과적인 예방에 대한 전략적 필요성을 더욱 강화시키고 있습니다.

카테터 재료, AI를 활용한 감염 추적, 표적 항균제 치료법 등의 개발로 제품 개발 및 도입이 가속화되고 있습니다. 의료기기 제조업체, 감염관리팀, 의료 IT 벤더 간의 전략적 협력으로 보다 통합된 데이터베이스 CRBSI 완화 전략이 가능해졌습니다. 전 세계 의료 시스템이 카테터 관련 합병증을 근절하기 위해 노력하는 가운데, CRBSI 예방이 표준화된 증거 기반, 기술 기반 프레임워크로 진화할 수 있을 것인가라는 결정적인 질문이 앞으로의 길을 형성하고 있습니다.

부문

치료 유형(항균제, 항생제 락 요법), 감염원(Coagulase 음성 포도상구균, 황색포도상구균, 장내 그람음성 진균, 효모, 장구균·연쇄구균, Pseudomonas, 기타 감염원), 유통 채널(병원 약국, 소매 약국, 온라인 약국)

조사 대상 기업의 예(주목 합계 42사)

  • 3M Company
  • AngioDynamics Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Biomerics LLC
  • Boston Scientific Corporation
  • Cook Medical LLC
  • ICU Medical Inc.
  • IntraSpecialist Pte Ltd.
  • Medcomp
  • Medline Industries LP
  • Medtronic plc
  • Merit Medical Systems Inc.
  • Navilyst Medical Inc.
  • Nexus Medical LLC
  • Poly Medicure Ltd.
  • Pursuit Vascular(acquired by ICU Medical)
  • Smiths Medical(now part of ICU Medical)
  • Teleflex Incorporated
  • Vygon SA

관세 영향 계수

Global Industry Analysts는 본국, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수입원가 증가, 수익성 하락, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국 <>중국 <>멕시코 <>캐나다 <>EU <>일본 <>인도 <>기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트를 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.06.16

Global Catheter-Related Bloodstream Infections Market to Reach US$1.9 Billion by 2030

The global market for Catheter-Related Bloodstream Infections estimated at US$1.5 Billion in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 4.0% over the analysis period 2024-2030. Anti-Microbial Agents, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Antibiotic Lock Therapy segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$398.9 Million While China is Forecast to Grow at 7.5% CAGR

The Catheter-Related Bloodstream Infections market in the U.S. is estimated at US$398.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$380.0 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Catheter-Related Bloodstream Infections (CRBSIs) Market - Key Trends & Drivers Summarized

Why Are Catheter-Related Bloodstream Infections a Persistent Challenge in Critical Care and Hospital Infection Control?

Catheter-related bloodstream infections (CRBSIs) remain a significant cause of morbidity, mortality, and increased healthcare costs in clinical settings-particularly in intensive care units, oncology wards, and long-term care facilities. These infections arise when pathogens colonize intravascular catheters, leading to systemic bloodstream infections that complicate treatment outcomes and extend hospital stays. As central venous catheters (CVCs) are widely used for medication administration, parenteral nutrition, and hemodynamic monitoring, CRBSIs represent a serious nosocomial risk that continues to strain hospital infection control protocols.

Despite improved awareness, the global burden of CRBSIs persists due to inconsistent adherence to aseptic insertion techniques, prolonged catheter dwell times, and antimicrobial resistance. The need to minimize preventable infections is intensifying as healthcare systems prioritize quality metrics, patient safety, and cost containment-driving sustained demand for advanced prevention tools, diagnostics, and bundled care solutions targeting CRBSIs.

How Are Innovations in Catheter Materials, Antimicrobial Coatings, and Infection Surveillance Improving CRBSI Prevention?

Medical device manufacturers are advancing catheter technologies through the use of antimicrobial and antiseptic coatings (e.g., silver sulfadiazine, chlorhexidine, and minocycline-rifampin) that inhibit microbial adhesion and biofilm formation. These coated catheters are increasingly adopted in high-risk settings to reduce infection rates without compromising vascular access functionality. Improvements in catheter insertion kits, securement devices, and transparent dressings are further enhancing infection barrier protection.

Electronic health record (EHR)-linked infection surveillance systems and real-time analytics platforms are also supporting early detection and tracking of CRBSIs. Standardized central line bundles, clinical decision support tools, and nurse-driven removal protocols are being implemented to drive compliance and accountability in line care. Additionally, point-of-care diagnostic tools and rapid culture systems are aiding timely pathogen identification and targeted antibiotic administration, improving patient outcomes.

Where Is Demand for CRBSI Prevention and Management Solutions Growing and Which Clinical Environments Are Driving Adoption?

North America leads global CRBSI prevention efforts, supported by well-established hospital quality reporting frameworks and stringent CMS and CDC guidelines. The U.S. continues to drive demand for coated catheters, diagnostic tests, and infection surveillance software. Europe follows with increasing adoption of catheter care bundles and region-wide patient safety initiatives. Asia-Pacific is witnessing strong growth in infection control markets, particularly in countries like India, China, and Japan, where expanding ICU infrastructure and rising surgical volumes are heightening CRBSI prevention priorities.

Key clinical environments include intensive care units, oncology departments, dialysis centers, and long-term acute care hospitals-settings where central venous access is common and patient vulnerability is high. Additionally, home infusion therapy and ambulatory care services are expanding the scope of CRBSI risk management beyond hospital walls, driving demand for portable infection prevention solutions and patient education tools.

What Is Fueling the Global Growth of the Catheter-Related Bloodstream Infections Market?

The global CRBSIs market is being driven by the rising use of vascular access devices, growing awareness of hospital-acquired infections (HAIs), and regulatory pressure to meet infection control benchmarks. As healthcare providers focus on reducing preventable harm and optimizing clinical outcomes, investment is increasing in bundled solutions that combine coated catheters, securement systems, and staff training protocols. The financial burden of CRBSIs-through increased treatment costs, penalties, and reputational risk-continues to reinforce the strategic imperative for effective prevention.

Innovation in catheter materials, AI-enabled infection tracking, and targeted antimicrobial therapies is accelerating product development and adoption. Strategic collaborations between device manufacturers, infection control teams, and health IT vendors are enabling more integrated, data-driven CRBSI mitigation strategies. As global health systems strive to eliminate catheter-associated complications, a defining question frames the path forward: Can CRBSI prevention evolve into a standardized, evidence-based, and technology-augmented framework-while ensuring cost-effectiveness, scalability, and patient safety across varied care delivery environments?

SCOPE OF STUDY:

The report analyzes the Catheter-Related Bloodstream Infections market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Anti-Microbial Agents, Antibiotic Lock Therapy); Source of Infection (Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas, Other Sources of Infection); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • 3M Company
  • AngioDynamics Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Biomerics LLC
  • Boston Scientific Corporation
  • Cook Medical LLC
  • ICU Medical Inc.
  • IntraSpecialist Pte Ltd.
  • Medcomp
  • Medline Industries LP
  • Medtronic plc
  • Merit Medical Systems Inc.
  • Navilyst Medical Inc.
  • Nexus Medical LLC
  • Poly Medicure Ltd.
  • Pursuit Vascular (acquired by ICU Medical)
  • Smiths Medical (now part of ICU Medical)
  • Teleflex Incorporated
  • Vygon SA

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Catheter-Related Bloodstream Infections - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increased Use of Central Venous Catheters in ICUs and Oncology Elevates Risk of CRBSIs
    • Adoption of Antimicrobial and Antiseptic-Coated Catheters Reduces Infection Incidence
    • Hospital Infection Control Programs Prioritize CRBSI Prevention Through Bundled Protocols
    • Real-Time Monitoring Devices and Smart Catheter Technologies Gain Traction in High-Risk Settings
    • Surveillance Systems and EHR Integration Enable Timely CRBSI Detection and Intervention
    • ICU Workflow Automation Enhances Data Capture and Standardization in Catheter Maintenance
    • Innovation in Catheter Materials With Bacteriostatic Properties Gains Market Share
    • Global Health Initiatives Address CRBSI Prevention in Low-Resource and Field Hospital Settings
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Catheter-Related Bloodstream Infections Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Catheter-Related Bloodstream Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Catheter-Related Bloodstream Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Anti-Microbial Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Anti-Microbial Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Anti-Microbial Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antibiotic Lock Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antibiotic Lock Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Antibiotic Lock Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Coagulase-Negative Staphylococcus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Coagulase-Negative Staphylococcus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Coagulase-Negative Staphylococcus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for S. aureus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for S. aureus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for S. aureus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Enteric Gram-Negative Bacilli by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Enteric Gram-Negative Bacilli by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Enteric Gram-Negative Bacilli by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Yeasts by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Yeasts by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Yeasts by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Enterococci & Streptococci by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Enterococci & Streptococci by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Enterococci & Streptococci by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Pseudomonas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Pseudomonas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Pseudomonas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Sources of Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Sources of Infection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Other Sources of Infection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • JAPAN
    • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • CHINA
    • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • EUROPE
    • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Catheter-Related Bloodstream Infections by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Catheter-Related Bloodstream Infections by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • FRANCE
    • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • GERMANY
    • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Catheter-Related Bloodstream Infections by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Catheter-Related Bloodstream Infections by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • INDIA
    • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Catheter-Related Bloodstream Infections by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Catheter-Related Bloodstream Infections by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Catheter-Related Bloodstream Infections by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Catheter-Related Bloodstream Infections by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030
  • AFRICA
    • Catheter-Related Bloodstream Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Catheter-Related Bloodstream Infections by Treatment Type - Anti-Microbial Agents and Antibiotic Lock Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Catheter-Related Bloodstream Infections by Treatment Type - Percentage Breakdown of Value Sales for Anti-Microbial Agents and Antibiotic Lock Therapy for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Catheter-Related Bloodstream Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Catheter-Related Bloodstream Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Catheter-Related Bloodstream Infections by Source of Infection - Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Catheter-Related Bloodstream Infections by Source of Infection - Percentage Breakdown of Value Sales for Coagulase-Negative Staphylococcus, S. aureus, Enteric Gram-Negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas and Other Sources of Infection for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제